BioNexus Gene Lab Corp. Total Liabilities and Equity
BioNexus Gene Lab Corp. (BGLC) had Total Liabilities and Equity of $8.73 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-14
- 2026-06-30: Liabilities and Equity $8.73M.
- 2026-03-31: Liabilities and Equity $9.04M.
- 2025-12-31: Liabilities and Equity $9.25M.
- 2025-09-30: Liabilities and Equity $7.62M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $8.73M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $9.04M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $9.25M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $7.62M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $9.42M 10-Q · filed 2025-08-18 |
| 2025-03-31 | $9.48M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $10.43M 10-K · filed 2026-04-14 |
| 2024-09-30 | $11.00M 10-Q · filed 2024-11-15 |
| 2024-06-30 | $11.14M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $11.16M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $11.40M 10-K · filed 2025-04-15 |
| 2023-09-30 | $11.47M 10-Q/A · filed 2024-03-26 |
| 2023-06-30 | $7.90M 10-Q · filed 2023-08-16 |
| 2023-03-31 | $8.19M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $8.74M 10-K · filed 2024-04-16 |
| 2022-09-30 | $7.80M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $8.37M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $9.18M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $9.57M 10-K · filed 2023-03-31 |
| 2021-09-30 | $9.77M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $9.45M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $9.90M 10-Q · filed 2021-05-18 |
| 2020-12-31 | $10.12M 10-K · filed 2022-04-06 |
| 2020-09-30 | $1.01M 10-Q/A · filed 2020-11-09 |
| 2020-06-30 | $1.06M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $1.13M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $1.23M 10-K · filed 2021-03-30 |
| 2019-09-30 | $1.34M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $1.51M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.61M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $1.65M 10-K · filed 2020-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |